Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,096 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Side Effects Clear all
Completed Phase 2 Interventional Results available

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

NCT01465802
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
Dacomitinib, Doxycycline, Probiotic, Alclometasone cream
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
79
States / cities
Duarte, California • Fullerton, California • Irvine, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 24, 2026, 8:51 AM EDT
Completed Not applicable Interventional Results available

Video-laryngoscope With a Novel Video-stylet for Difficult Intubation

NCT01215695
View directory record Official record
Conditions
Difficult Endotracheal Intubation
Interventions
aScope (Ambu Inc. 6740 Baymeadow Drive Glen Burnie, MD), Control
Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 8, 2017 · Synced Oct 24, 2026, 8:51 AM EDT
Not yet recruiting Phase 2 Interventional

Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity

NCT07572175
View directory record Official record
Conditions
Anthracycline-induced Cardiotoxicity, Lymphoma, Chemotherapy, Cardiotoxicity
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 24, 2026, 8:51 AM EDT
Completed Not applicable Interventional

Neuroplasticity-Based Cognitive Remediation for Chemotherapy-Related Cognitive Impairment

NCT04230863
View directory record Official record
Conditions
Cancer Survivors, Chemotherapy-related Cognitive Impairment
Interventions
Neuroplasticity-based Computerized Cognitive Remediation
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
35 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 24, 2026, 8:51 AM EDT
Not listed Not applicable Interventional

Can Fasting Decrease the Side Effects of Chemotherapy?

NCT04027478
View directory record Official record
Conditions
Chemotherapy Effect, Chemotherapeutic Toxicity, Fasting
Interventions
FMD
Dietary Supplement
Lead sponsor
Sutter Health
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 24, 2026, 8:51 AM EDT
Completed Phase 2 Interventional

D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients

NCT00047476
View directory record Official record
Conditions
Fatigue, Neoplasms
Interventions
dexmethylphenidate(d-mph)
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
21
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 24, 2026, 8:51 AM EDT
Completed Phase 2 Interventional

Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy

NCT00055718
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Interventions
silymarin
Dietary Supplement
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
2 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
7
States / cities
Miami, Florida • Mineola, New York • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 24, 2026, 8:51 AM EDT
Withdrawn Phase 4 Interventional

RCT: Trazodone vs Quetiapine vs Placebo for Treating ICU Delirium (TraQ)

NCT05085808
View directory record Official record
Conditions
Delirium, Morality, Quality of Life, Psych, Treatment Side Effects
Interventions
Trazodone, Quetiapine, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 24, 2026, 8:51 AM EDT
Completed Phase 4 Interventional Results available

Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients

NCT02764697
View directory record Official record
Conditions
Uveitis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Scleritis, Clinically Significant Macular Edema
Interventions
H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
Drug
Lead sponsor
Tampa Bay Uveitis Center, LLC
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 24, 2026, 8:51 AM EDT
Completed Not applicable Interventional Results available

Comparing Everolimus and Sirolimus in Renal Transplant Recipients

NCT01976390
View directory record Official record
Conditions
Renal Failure
Interventions
Everolimus, Sirolimus
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 24, 2026, 8:51 AM EDT
Terminated No phase listed Observational

Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoietic Stem Cell Transplant Recipients

NCT00504218
View directory record Official record
Conditions
Hypopituitarism, Hypogonadism, Thyroid Dysfunction, Bone Diseases, Metabolic
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 24 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Oct 24, 2026, 8:51 AM EDT
Completed Phase 2 Interventional

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation

NCT01459926
View directory record Official record
Conditions
Opioid Induced Constipation
Interventions
TD-1211, Placebo
Drug
Lead sponsor
Glycyx Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Foley, Alabama
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 24, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease

NCT04734210
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.02% Betamethasone Sodium Phosphate, 0.04% Betamethasone Sodium Phosphate, Placebo
Drug
Lead sponsor
Surface Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
28
States / cities
Dothan, Alabama • Azusa, California • Mission Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 24, 2026, 8:51 AM EDT
Terminated Not applicable Interventional Results available

Measurement of the Radiation Dose Cuticles Using Electron Paramagnetic Resonance (EPR)

NCT00904189
View directory record Official record
Conditions
Irradiation; Adverse Effect
Interventions
Standard of care given for treatment of cancer
Radiation
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 24, 2026, 8:51 AM EDT
Completed No phase listed Observational

Association Between Genetic Variant Scores and Warfarin Effect

NCT03894878
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Intracardiac Thrombus, Pulmonary Embolism, Venous Thromboembolic Disease
Interventions
Not listed
Lead sponsor
Cipherome, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 24, 2026, 8:51 AM EDT
Completed No phase listed Observational Results available

Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors

NCT01015326
View directory record Official record
Conditions
Skin Toxicities
Interventions
Questionnaire
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 24, 2026, 8:51 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

NCT07023289
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Telisotuzumab Adizutecan, Standard of Care
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Huntsville, Alabama • Fullerton, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 24, 2026, 8:51 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers

NCT07769502
View directory record Official record
Conditions
Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma
Interventions
Telisotuzumab Adizutecan, Gemcitabine, Nab-Paclitaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Hattiesburg, Mississippi
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 24, 2026, 8:51 AM EDT
Not listed Phase 1 Interventional

Post IVIG Medication in Children With Immune Thrombocytopenia

NCT04741139
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Acetaminophen and Diphenhydramine Only Product
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Month to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 24, 2026, 8:51 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Patient-Reported Outcome Version of the Common Criteria for Adverse Events

NCT04050072
View directory record Official record
Conditions
Survivorship, Cancer
Interventions
Childhood Cancer Survivors (CCSS), SJLIFE, Community non-cancer control
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
16 Years and older
Enrollment
837 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 24, 2026, 8:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

No Post Intubation Laryngeal Symptoms

NCT05383417
View directory record Official record
Conditions
Sore-throat, Dysphonia, Dysphagia, Intubation Complication, Anesthesia Intubation Complication, Anesthesia Morbidity, Anesthesia Complication, Anesthesia; Adverse Effect, Anesthesia; Reaction, Throat Disorder, Throat; Wound, Throat Injury
Interventions
EndoClip
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 24, 2026, 8:51 AM EDT
Completed Phase 4 Interventional Results available

Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography

NCT01475097
View directory record Official record
Conditions
Drug Safety
Interventions
Iodixanol, Iopamidol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 24, 2026, 8:51 AM EDT
Completed No phase listed Observational

The CAROLE (CArdiac Related Oncologic Late Effects) Study

NCT03235427
View directory record Official record
Conditions
Coronary Artery Disease, Cardiac Disease, Cardiac Toxicity, Radiation, Radiation Therapy, Atherosclerotic Heart Disease, Cardiotoxicity, Breast Cancer, Lung Cancer, Lymphoma, Cancer, Carcinoma, Intraductal, Noninfiltrating
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
26 Years to 78 Years · Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 24, 2026, 8:51 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

NCT05308654
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
ABBV-453, Dexamethasone, Daratumumab, Lenalidomide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Stanford, California • Miami, Florida • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 24, 2026, 8:51 AM EDT